Clinical Edge Journal Scan

Depression and anxiety linked to reduced probability of achieving sustained MDA in PsA


 

Key clinical point : The presence of depression/anxiety symptoms reduces the probability of achieving sustained minimal disease activity (MDA) in patients with psoriatic arthritis (PsA), regardless of the method used to define depression/anxiety.

Major finding: When depression/anxiety was defined as a score of 38 or lower on the Mental Component Summary of the Short Form-36 questionnaire (definition 1), the odds ratio (OR) for reaching sustained MDA was 0.30 ( P less than .0001). The OR values were 0.34 ( P less than .0001) and 0.47 ( P less than .0001) for a score of 56 or lower on the Mental Health sub-scale (definition 2) and for rheumatologist’s report of a diagnosis or treatment for depression/anxiety (definition 3), respectively.

Study details: The data come from a study of 743 patients with PsA.

Disclosures: No study sponsor was identified. Several of the authors are affiliated with the Psoriatic Disease Program of the Krembil Research Institute of University Health Network in Toronto, which is supported by the Krembil Foundation. Dr. A Wong was supported by a Krembil Psoriatic Arthritis Fellowship and Dr. V Chandran was supported by a Pfizer Chair Rheumatology Research Award from the Department of Medicine, University of Toronto.

Source: Wong A et al. Arthritis Care Res (Hoboken). 2021 Mar 4. doi: 10.1002/acr.24593 .

Recommended Reading

Recent psoriasis pathophysiology insights carry treatment implications
Psoriatic Arthritis ICYMI
To improve psoriatic arthritis outcomes, address common comorbidities
Psoriatic Arthritis ICYMI
Checkpoint inhibitor–induced rheumatic complications often arise late
Psoriatic Arthritis ICYMI
FDA warning letters target OTC cannabidiol product claims for pain relief
Psoriatic Arthritis ICYMI
COVID-19 vaccination in RMD patients: Safety data “reassuring”
Psoriatic Arthritis ICYMI
Experts highlight recent breakthroughs in psoriatic arthritis
Psoriatic Arthritis ICYMI
Is pain linked to mortality risk in patients with psoriatic arthritis?
Psoriatic Arthritis ICYMI
PsA: Brodalumab demonstrates favorable efficacy in phase 3 trials
Psoriatic Arthritis ICYMI
Continuing ixekizumab superior to withdrawal in stable psoriatic arthritis
Psoriatic Arthritis ICYMI
Risk factors for progression from subclinical to clinical psoriatic arthritis
Psoriatic Arthritis ICYMI